A single extra copy of Dscr1 improves survival of mice developing spontaneous lung tumors through suppression of tumor angiogenesis

Cancer Letters

Volumn 342, Issue 1, 2014, Pages 70-81

  Shin, Jimin ^a   Lee, Jang Choon ^a   Baek, Kwan Hyuck ^a  

^a Sungkyunkwan University School of Medicine   (South Korea)

Author keywords

Angiogenesis; Cancer; Down syndrome; Dscr1; Spontaneous lung tumorigenesis

Indexed keywords

TRANSCRIPTION FACTOR NFAT;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; APOPTOSIS; ARTICLE; CANCER CELL; CANCER GRADING; CANCER GROWTH; CANCER SURVIVAL; CAPILLARY DENSITY; CELL PROLIFERATION; DSCR1 GENE; ENDOTHELIUM CELL; GENE DUPLICATION; GENE EXPRESSION; GENE FUNCTION; LUNG TUMOR; MOUSE; NEOVASCULARIZATION (PATHOLOGY); NONHUMAN; ONCOGENE; ONCOGENE K RAS; PRIORITY JOURNAL; PROTEIN EXPRESSION; TRISOMY; TUMOR GROWTH; TUMOR VOLUME; UPREGULATION;

ANGIOGENESIS; CANCER; DOWN SYNDROME; DSCR1; SPONTANEOUS LUNG TUMORIGENESIS;

ANIMALS; APOPTOSIS; CELL LINE, TUMOR; CELL PROLIFERATION; DOWN SYNDROME; GENE DOSAGE; GENE EXPRESSION; HUMANS; INTRACELLULAR SIGNALING PEPTIDES AND PROTEINS; LUNG NEOPLASMS; MALE; MICE; MICE, 129 STRAIN; MICE, INBRED C57BL; MICE, TRANSGENIC; MUSCLE PROTEINS; MUTATION, MISSENSE; NEOVASCULARIZATION, PATHOLOGIC; PROTO-ONCOGENE PROTEINS P21(RAS); TUMOR BURDEN; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

MUS; MUS MUSCULUS;

EID: 84887617850     PISSN: 03043835     EISSN: 18727980     Source Type: Journal    
DOI: 10.1016/j.canlet.2013.08.047     Document Type: Article

References (56)

1. D. Satgé, A.J. Sasco, N.L. Carlsen, C.A. Stiller, H. Rubie, B. Hero, B. de Bernardi, J. de Kraker, C. Coze, P. Kogner, F. Langmark, F.G. Hakvoort-Cammel, D. Beck, N. von der Weid, S. Parkes, O. Hartmann, R.J. Lippens, W.A. Kamps, D. Sommelet D, A lack of neuroblastoma in Down syndrome: a study from 11 European countries, Cancer Res. 58 (1998) 448-452.
2. Hasle H., Clemmensen I.H., Mikkelsen M. Risks of leukaemia and solid tumors in individuals with Down's syndrome. Lancet 2000, 355:165-169.
3. Satgé D., Sasco A.J., Pujol H., Rethoré M.O. Breast cancer in women with trisomy 21. Bull. Acad. Natl. Med. 2001, 185:1239-1252.
4. Yang Q., Rasmussen S.A., Friedman J.M. Mortality associated with Down's syndrome in the USA from, To 1997: a population-based study. Lancet 1983, 359(2002):1019-1025.
5. Patja K., Pukkala E., Sund R., Iivanainen M., Kaski M. Cancer incidence of persons with Down syndrome in Finland: a population-based study. Int. J. Cancer 2006, 118:1769-1772.
6. Sullivan S.G., Hussain R., Glasson E.J., Bittles A.H. The profile and incidence of cancer in Down syndrome. J. Intellect. Disabil. Res. 2007, 51:228-231.
7. Folkman J. Role of angiogenesis in tumor growth and metastasis. Semin. Oncol. 2002, 29:15-18.
8. Fulcher T., Griffin M., Crowley S., Firth R., Acheson R., O'Meara N. Diabetic retinopathy in Down's syndrome. Br. J. Ophthalmol. 1998, 82:407-409.
9. Murdoch J.C., Rodger J.C., Rao S.S., Fletcher C.D., Dunnigan M.G. Down's syndrome: an atheroma-free model?. Br. Med. J. 1977, 1977:226-228.
10. Zorick T.S., Mustacchi Z., Bando S.Y., Zatz M., Moreira-Filho C.A., Olsen B., Passos-Bueno M.R. High serum endostatin levels in Down syndrome: implications for improved treatment and prevention of solid tumours. Eur. J. Hum. Genet. 2001, 9:811-814.
11. Lee N.V., Sato M., Annis D.S., Loo J.A., Wu L., Mosher D.F., Iruela-Arispe M.L. ADAMTS1 mediates the release of antiangiogenic polypeptides from TSP1 and 2. EMBO J. 2006, 25:5270-5283.
12. Fuentes J.J., Pritchard M.A., Estivill X. Genomic organization, alternative splicing, and expression patterns of the DSCR1 (Down syndrome candidate region 1) gene. Genomics 1997, 44:358-361.
13. Ryeom S., Greenwald R.J., Sharpe A.H., McKeon F. The threshold pattern of calcineurin-dependent gene expression is altered by loss of the endogenous inhibitor calcipressin. Nat. Immunol. 2003, 4:874-881.
14. S. Ryeom, K.H. Baek, M.J. Rioth, R.C. Lynch, A. Zaslavsky, A. Birsner, S.S. Yoon, F. McKeon F, Targeted deletion of the calcineurin inhibitor DSCR1 suppresses tumor growth, Cancer Cell. 13 (2008) 420-431.
15. Hernández G.L., Volpert O.V., Iñiguez M.A., Lorenzo E., Martínez-Martínez S., Grau R., Fresno M., Redondo J.M. Selective inhibition of vascular endothelial growth factor-mediated angiogenesis by cyclosporin A: roles of the nuclear factor of activated T cells and cyclooxygenase 2. J. Exp. Med. 2001, 193:607-620.
16. Hesser B.A., Liang X.H., Camenisch G., Yang S., Lewin D.A., Scheller R., Ferrara N., Gerber H.P. Down syndrome critical region protein 1 (DSCR1), a novel VEGF target gene that regulates expression of inflammatory markers on activated endothelial cells. Blood 2004, 104:149-158.
17. Iizuka M., Abe M., Shiiba K., Sasaki I., Sato Y. Down syndrome candidate region 1, a downstream target of VEGF, participates in endothelial cell migration and angiogenesis. J. Vasc. Res. 2004, 41:334-344.
18. Minami T., Horiuchi K., Miura M., Abid M.R., Takabe W., Noguchi N., Kohro T., Ge X., Aburatani H., Hamakubo T., Kodama T., Aird W.C. Vascular endothelial growth factor- and thrombin-induced termination factor, Down syndrome critical region-1, attenuates endothelial cell proliferation and angiogenesis. J. Biol. Chem. 2004, 279:50537-50554.
19. Yao Y.G., Duh E.J. VEGF selectively induces Down syndrome critical region 1 gene expression in endothelial cells: a mechanism for feedback regulation of angiogenesis?. Biochem. Biophys. Res. Commun. 2004, 321:648-656.
20. Baek K.H., Zaslavsky A., Lynch R.C., Britt C., Okada Y., Siarey R.J., Lensch M.W., Park I.H., Yoon S.S., Minami T., Korenberg J.R., Folkman J., Daley G.Q., Aird W.C., Galdzicki Z., Ryeom S. Down's syndrome suppression of tumour growth and the role of the calcineurin inhibitor DSCR1. Nature 2009, 459:1126-1130.
21. Reynolds L.E., Watson A.R., Baker M., Jones T.A., D'Amico G., Robinson S.D., Joffre C., Garrido-Urbani S., Rodriguez-Manzaneque J.C., Martino-Echarri E., Aurrand-Lions M., Sheer D., Dagna-Bricarelli F., Nizetic D., McCabe C.J., Turnell A.S., Kermorgant S., Imhof B.A., Adams R., Fisher E.M., Tybulewicz V.L., Hart I.R., Hodivala-Dilke K.M. Tumour angiogenesis is reduced in the Tc1 mouse model of Down's syndrome. Nature 2010, 465:813-817.
22. Jackson E.L., Willis N., Mercer K., Bronson R.T., Crowley D., Montoya R., Jacks T., Tuveson D.A. Analysis of lung tumor initiation and progression using conditional expression of oncogenic K-ras. Genes Dev. 2001, 15:3243-3248.
23. Santos A.M., Jung J., Aziz N., Kissil J.L., Puré E. Targeting fibroblast activation protein inhibits tumor stromagenesis and growth in mice. J. Clin. Invest. 2009, 119:3613-3625.
24. Fasbender A., Lee J.H., Walters R.W., Moninger T.O., Zabner J., Welsh M.J. Incorporation of adenovirus in calcium phosphate precipitates enhances gene transfer to airway epithelia in vitro and in vivo. J. Clin. Invest. 1998, 102:184-193.
25. Jackson E.L., Olive K.P., Tuveson D.A., Bronson R., Crowley D., Brown M., Jacks T. The differential effects of mutant p53 alleles on advanced murine lung cancer. Cancer Res. 2005, 65:10280-10288.
26. Johannessen C.M., Reczek E.E., James M.F., Brems H., Legius E., Cichowski K. The NF1 tumor suppressor critically regulates TSC2 and mTOR. Proc. Natl. Acad. Sci. USA 2005, 102:8573-8578.
27. Heidebrecht F., Heidebrecht A., Schulz I., Behrens S.E., Bader A. Improved semiquantitative Western blot technique with increased quantitative range. J. Immunol. Methods 2009, 345:40-48.
28. C.R. Yellaturu, S.K. Ghosh, R.K. Rao, L.K. Jennings, A. Hassid, G.N. Rao GN, A potential role for nuclear factor of activated T-cells in receptor tyrosine kinase and G-protein-coupled receptor agonist-induced cell proliferation, Biochem. J. 368 (2002) 183-190.
29. Heit J.J., Apelqvist A.A., Gu X., Winslow M.M., Neilson J.R., Crabtree G.R., Kim S.K. Calcineurin/NFAT signalling regulates pancreatic beta-cell growth and function. Nature 2006, 443:345-349.
30. Robbs B.K., Cruz A.L., Werneck M.B., Mognol G.P., Viola J.P. Dual roles for NFAT transcription factor genes as oncogenes and tumor suppressors. Mol. Cell. Biol. 2008, 28:7168-7181.
31. Yiu G.K., Toker A. NFAT induces breast cancer cell invasion by promoting the induction of cyclooxygenase-2. J. Biol. Chem. 2006, 281:12210-12217.
32. Marafioti T., Pozzobon M., Hansmann M.L., Ventura R., Pileri S.A., Roberton H., Gesk S., Gaulard P., Barth T.F., Du M.Q., Leoncini L., Möller P., Natkunam Y., Siebert R., Mason D.Y. The NFATc1 transcription factor is widely expressed in white cells and translocates from the cytoplasm to the nucleus in a subset of human lymphomas. Br. J. Haematol. 2005, 128:333-342.
33. Pham L.V., Tamayo A.T., Yoshimura L.C., Lin-Lee Y.C., Ford R.J. Constitutive NF-κB and NFAT activation in aggressive B-cell lymphomas synergistically activates the CD154 gene and maintains lymphoma cell survival. Blood 2005, 106:3940-3947.
34. Zhang K., Li N., Chen Z., Shao K., Zhou F., Zhang C., Mu X., Wan J., Li B., Feng X., Shi S., Xiong M., Cao K., Wang X., Huang C., He J. High expression of nuclear factor of activated T cells in Chinese primary non-small cell lung cancer tissues. Int. J. Biol. Markers 2007, 22:221-225.
35. Chen Z.L., Zhao S.H., Wang Z., Qiu B., Li B.Z., Zhou F., Tan X.G., He J. Expression and unique functions of four nuclear factor of activated T cells isoforms in non-small cell lung cancer. Chin. J. Cancer. 2011, 30:62-68.
36. Cho Y.J., Abe M., Kim S.Y., Sato Y. Raf-1 is a binding partner of DSCR1. Arch. Biochem. Biophys. 2005, 439:121-128.
37. Folkman J. Tumor angiogenesis factor. Cancer Res. 1974, 34:2109-2113.
38. Singh R.P., Deep G., Chittezhath M., Kaur M., Dwyer-Nield L.D., Malkinson A.M., Agarwal R. Effect of silibinin on the growth and progression of primary lung tumors in mice. J. Natl Cancer Inst. 2006, 98:846-855.
39. Rak J., Mitsuhashi Y., Bayko L., Filmus J., Shirasawa S., Sasazuki T., Kerbel R.S. Mutant ras oncogenes upregulate VEGF/VPF expression: implications for induction and inhibition of tumor angiogenesis. Cancer Res. 1995, 55:4575-4580.
40. J. Milanini, F. Viñals, J. Pouysségur, G. Pagès G, p42/p44 MAP Kinase module plays a key role in the transcriptional regulation of vascular endothelial growth factor gene in fibroblasts. J. Biol. Chem. 273 (1998) 18165-18172.
41. Folkman J. Tumor angiogenesis: therapeutic implications. N. Engl. J. Med. 1971, 285:1182-1186.
42. Prewett M., Huber J., Li Y., Santiago A., O'Connor W., King K., Overholser J., Hooper A., Pytowski B., Witte L., Bohlen P., Hicklin D.J. Antivascular endothelial growth factor receptor (fetal liver kinase 1) monoclonal antibody inhibits tumor angiogenesis and growth of several mouse and human tumors. Cancer Res. 1999, 59:5209-5218.
43. Holmgren L., O'Reilly M.S., Folkman J. Dormancy of micrometastases: balanced proliferation and apoptosis in the presence of angiogenesis suppression. Nat. Med. 1995, 1:149-153.
44. O'Reilly M.S., Holmgren L., Chen C., Folkman J. Angiostatin induces and sustains dormancy of human primary tumors in mice. Nat. Med. 1996, 2:689-692.
45. Flockhart R.J., Armstrong J.L., Reynolds N.J., Lovat P.E. NFAT signalling is a novel target of oncogenic BRAF in metastatic melanoma. Br. J. Cancer 2009, 101:1448-1455.
46. Min-mediated tumours in mouse models of Down's syndrome. Nature 2008, 451:73-75.
47. Lee Y.J., Koch M., Karl D., Torres-Collado A.X., Fernando N.T., Rothrock C., Kuruppu D., Ryeom S., Iruela-Arispe M.L., Yoon S.S. Variable inhibition of thrombospondin 1 against liver and lung metastases through differential activation of metalloproteinase ADAMTS1. Cancer Res. 2010, 70:948-956.
48. Yang A., Reeves R.H. Increased survival following tumorigenesis in Ts65Dn mice that model Down's Syndrome. Cancer Res. 2011, 71:3573-3581.
49. Tomlinson J., Barsky S.H., Nelson S., Singer S., Pezeshki B., Lee M.C., Eilber F., Nguyen M. Different patterns of angiogenesis in sarcomas and carcinomas. Clin. Cancer Res. 1999, 5:3516-3522.
50. N. Weidner, J. Folkman, Tumoral vascularity as a prognostic factor in cancer, Imp. Adv. Oncol. (1996) 167-190.
51. Ohsawa M., Tomita Y., Kuratsu S., Kanno H., Aozasa K. Angiogenesis in malignant fibrous histiocytoma. Oncology 1995, 52:51-54.
52. Saenz N.C., Heslin M.J., Adsay V., Lewis J.J., Leung D.H., LaQuaglia M.P., Brennan M.F. Neovascularity and clinical outcome in high-grade extremity soft tissue sarcomas. Ann. Surg. Oncol. 1998, 5:48-53.
53. Bush C.R., Havens J.M., Necela B.M., Su W., Chen L., Yanagisawa M., Anastasiadis P.Z., Guerra R., Luxon B.A., Thompson E.A. Functional genomic analysis reveals cross-talk between peroxisome proliferator-activated receptor gamma and calcium signaling in human colorectal cancer cells. J. Biol. Chem. 2007, 282:23387-23401.
54. Harris C.D., Ermak G., Davies K.J. Multiple roles of the DSCR1 (Adapt78 or RCAN1) gene and its protein product calcipressin 1 (or RCAN1) in disease. Cell. Mol. Life Sci. 2005, 62:2477-2486.
55. Liu Y., Zhang Y., Min J., Liu L.L., Ma N.Q., Feng Y.M., Liu D., Wang P.Z., Huang D.D., Zhuang Y., Zhang H.L. Calcineurin promotes proliferation, migration, and invasion of small cell lung cancer. Tumour Biol. 2010, 31:199-207.
56. Werneck M.B., Vieira-de-Abreu A., Chammas R., Viola J.P. NFAT1 transcription factor is central in the regulation of tissue microenvironment for tumor metastasis. Cancer Immunol. Immunother. 2011, 60:537-546.